Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

12 Months Report from a Phase 3 Study of Plerixafor+G-CSF Vs. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with Multiple Myeloma

John F. DiPersio, MD, PhD, Edward A. Stadtmauer, MD, Auayporn P. Nademanee, Ivana NM Micallef, MD, Patrick J. Stiff, MD, Gary Bridger, PhD, Gary Calandra, MD, PhD

Blood (2008) 112 (11): 3312.

https://doi.org/10.1182/blood.V112.11.3312.3312

Published: 2008

Journal Articles

Months Report from the Phase 3 Study of Plerixafor+G-CSF VS. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with NHL.

John F. DiPersio, MD, PhD, Ivana NM Micallef, Patrick J. Stiff, MD, Brian J. Bolwell, MD, Richard Thomas Maziarz, MD, Gary Bridger, PhD, Gary Calandra, MD, PhD

Blood (2008) 112 (11): 1136.

https://doi.org/10.1182/blood.V112.11.1136.1136

Published: 2008

Journal Articles

Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Following Autologous Hematopoietic Stem Cell Transplant in Patients with Non-Hodgkin’s Lymphoma and Multiple Myeloma.

Patrick J. Stiff, MD, Ivana NM Micallef, Auayporn P. Nademanee, Edward A. Stadtmauer, MD, Richard Thomas Maziarz, MD, Brian J. Bolwell, MD, Gary Bridger, PhD, Gary Calandra, MD, PhD, Jennifer Angell, MS, John F. DiPersio, MD, PhD

Blood (2008) 112 (11): 2175.

https://doi.org/10.1182/blood.V112.11.2175.2175

Published: 2008

Journal Articles

The Effect of Rituximab on Mobilization with AMD3100 Plus G-CSF in Patients with Relapsed or Refractory NHL or HD.

Jonathan L. Kaufman, MD, Amanda M. Cook, CCRP, Christopher Flowers, MD, Amelia A. Langston, MD, Sagar Lonial, MD, Mary Jo Lechowicz, MD, H. Jean Khoury, MD, Gary Calandra, MD, Ned Waller, MD, PhD

Blood (2007) 110 (11): 1912.

https://doi.org/10.1182/blood.V110.11.1912.1912

Published: 2007

Journal Articles

A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. Placebo+G-CSF in Non-Hodgkin’s Lymphoma (NHL) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.

John F. DiPersio, MD, PhD, Ivana Micallef, MD, Patrick J. Stiff, MD, Brian J. Bolwell, MD, Richard Thomas Maziarz, MD, J. Angell, MS, G. Bridger, PhD, Gary Calandra, MD, 3101 Investigators7

Blood (2007) 110 (11): 601.

https://doi.org/10.1182/blood.V110.11.601.601

Published: 2007

Journal Articles

Successful Stem Cell Mobilization Rescue by AMD3100 (Plerixafor)+G-CSF for Patients Who Failed Primary Mobilization: Results from the Phase III (3101-NHL) Study.

Ivana Micallef, MD, Patrick J. Stiff, MD, John F. DiPersio, MD, PhD, Richard Thomas Maziarz, MD, John M. McCarty, MD, Jennifer Angell, MS, Gary Bridger, PhD, Gary Calandra, MD, on behalf of the 3101 Investigators7

Blood (2007) 110 (11): 602.

https://doi.org/10.1182/blood.V110.11.602.602

Published: 2007

Journal Articles

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+Placebo for Mobilization in Multiple Myeloma (MM) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.

John DiPersio, MD, PhD, Edward A. Stadtmauer, MD, Auayporn P. Nademanee, MD, Patrick Stiff, MD, Ivana Micallef, MD, J. Angell, MS, G. Bridger, PhD, Gary Calandra, MD, for the 3102 Investigators7

Blood (2007) 110 (11): 445.

https://doi.org/10.1182/blood.V110.11.445.445

Published: 2007

Journal Articles

Pharmacokinetics of Plerixafor (AMD3100) in Volunteers with Renal Impairment.

Ronald MacFarland, PhD, Reginal B. Ewesuedo, MD, Karin Badel, Gary Calandra, MD

Blood (2007) 110 (11): 2878.

https://doi.org/10.1182/blood.V110.11.2878.2878

Published: 2007

Journal Articles

Rescue from Failed Growth Factor and/or Chemotherapy HSC Mobilization with G-CSF and AMD3100: An Institutional Experience.

Richard Thomas Maziarz, MD, Adam Dunn, BS, Lisa Hansen, RN, Keith Hansen, MD, Jose F. Leis, MD, PhD, Brandon Hayes-Lattin, MD, Tibor Kovacsovics, MD, Gary Calandra, MD, Cedar Fowler, BA

Blood (2006) 108 (11): 5460.

https://doi.org/10.1182/blood.V108.11.5460.5460

Published: 2006

Journal Articles

HLA-Matched Sibling Donor Stem Cell Mobilization Can Be Safely and Effectively Reduced from a Five Day to a One Day Process by a Direct Antagonist of the CXCR4/SDF-1 Interaction.

Steven M. Devine, MD, Ravi Vij, MD, Laura Todt, RN, Kiley McLaughlin, BS, Nicholas Fisher, BA, Natalie Morris, Daniel C. Link, MD, Gary Calandra, MD, Gary Bridger, PhD, John F. DiPersio, MD, PhD

Blood (2006) 108 (11): 53.

https://doi.org/10.1182/blood.V108.11.53.53

Published: 2006

Journal Articles

Single Agent AMD3100 Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation in Patients with Multiple Myeloma (MM).

Neal Flomenberg, MD, Raymond Comenzo, MD, Karin Badel, Gary Calandra, MD

Blood (2006) 108 (11): 3381.

https://doi.org/10.1182/blood.V108.11.3381.3381

Published: 2006

Journal Articles

CD34+ Cells Mobilized with the New CXCR4 Antagonist AMD3100 + G-CSF Show Increased Anti-Apoptotic, Cell Cycle, DNA Repair and Cell Motility-Associated Gene Expression When Compared to G-CSF Mobilization Alone.

Timon Seeger, Patrick Maier, PhD, Li Li, PhD, Stephanie Laufs, PhD, Volker Eckstein, PhD, Gary Bridger, PhD, Gary Calandra, MD, PhD, Frederik Wenz, MD, Hartmut Goldschmidt, MD, Anthony D. Ho, MD, Stefan Fruehauf, MD

Blood (2005) 106 (11): 4264.

https://doi.org/10.1182/blood.V106.11.4264.4264

Published: 2005

Journal Articles

A Pilot Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients with Advanced Hematological Malignancies.

Steven M. Devine, MD, Leslie Andritsos, MD, Laura Todt, Ravi Vij, MD, Jesper Bonde, PhD, David Hess, PhD, Jan Nolta, PhD, Dan Link, MD, Gary Bridger, PhD, Gary Calandra, MD, John F. DiPersio, MD, PhD

Blood (2005) 106 (11): 299.

https://doi.org/10.1182/blood.V106.11.299.299

Published: 2005

Journal Articles

The CXCR4-Antagonist AMD3100 Augments the Number of Mobilized Peripheral Blood Progenitor Cells (PBPC) When Added to a G-CSF Standard Mobilization Regime and AMD3100-Mobilized PBPC Result in Rapid Hematopoietic Reconstitution after Autologous Transplantation.

Stefan Fruehauf, MD, Timon Seeger, Julian Topaly, MD, Doris Herrmann, PhD, Falk Dillmann, Per Humpert, MD, Gary Calandra, MD, PhD, Stephanie Laufs, PhD, Hartmut Goldschmidt, MD, Anthony D. Ho, MD

Blood (2005) 106 (11): 1961.

https://doi.org/10.1182/blood.V106.11.1961.1961

Published: 2005

Journal Articles

The CXCR4 Antagonist AMD3100 Mobilizes a More Primitive Subset of CD34+ Cells Than G-CSF.

Timon Seeger, Marlon Veldwijk, PhD, Gary Bridger, PhD, Gary Calandra, MD, PhD, Hartmut Goldschmidt, MD, Anthony Ho, MD, Stefan Fruehauf, MD

Blood (2005) 106 (11): 1969.

https://doi.org/10.1182/blood.V106.11.1969.1969

Published: 2005

Journal Articles

AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma.

Patrick Stiff, MD, Ivana Micallef, MD, Philip McCarthy, MD, Margarida Magalhaes-Silverman, MD, Neal Flomenberg, MD, Daniel Weisdorf, MD, Guido Tricot, MD, Mary Territo, MD, Rafat Abonour, MD, Karin Badel, Gary Calandra, MD/PhD

Blood (2004) 104 (11): 2847.

https://doi.org/10.1182/blood.V104.11.2847.2847

Published: 2004

Journal Articles

A Pilot Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients with Advanced Hematological Malignancies.

Steven M. Devine, MD, Jesper Bonde, PhD, David A. Hess, PhD, Terri M. Edwards, Daniel C. Link, MD, Diane Sempek, Gary Calandra, MD, Karin Badel, Jan A. Nolta, MD, John F. DiPersio, MD, PhD

Blood (2004) 104 (11): 3341.

https://doi.org/10.1182/blood.V104.11.3341.3341

Published: 2004

NARROW

12 Months Report from a Phase 3 Study of Plerixafor+G-CSF Vs. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with Multiple Myeloma

Months Report from the Phase 3 Study of Plerixafor+G-CSF VS. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with NHL.

Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Following Autologous Hematopoietic Stem Cell Transplant in Patients with Non-Hodgkin’s Lymphoma and Multiple Myeloma.

The Effect of Rituximab on Mobilization with AMD3100 Plus G-CSF in Patients with Relapsed or Refractory NHL or HD.

A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. Placebo+G-CSF in Non-Hodgkin’s Lymphoma (NHL) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.

Successful Stem Cell Mobilization Rescue by AMD3100 (Plerixafor)+G-CSF for Patients Who Failed Primary Mobilization: Results from the Phase III (3101-NHL) Study.

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+Placebo for Mobilization in Multiple Myeloma (MM) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.

Pharmacokinetics of Plerixafor (AMD3100) in Volunteers with Renal Impairment.

Rescue from Failed Growth Factor and/or Chemotherapy HSC Mobilization with G-CSF and AMD3100: An Institutional Experience.

HLA-Matched Sibling Donor Stem Cell Mobilization Can Be Safely and Effectively Reduced from a Five Day to a One Day Process by a Direct Antagonist of the CXCR4/SDF-1 Interaction.

Single Agent AMD3100 Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation in Patients with Multiple Myeloma (MM).

CD34+ Cells Mobilized with the New CXCR4 Antagonist AMD3100 + G-CSF Show Increased Anti-Apoptotic, Cell Cycle, DNA Repair and Cell Motility-Associated Gene Expression When Compared to G-CSF Mobilization Alone.

A Pilot Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients with Advanced Hematological Malignancies.

The CXCR4-Antagonist AMD3100 Augments the Number of Mobilized Peripheral Blood Progenitor Cells (PBPC) When Added to a G-CSF Standard Mobilization Regime and AMD3100-Mobilized PBPC Result in Rapid Hematopoietic Reconstitution after Autologous Transplantation.

The CXCR4 Antagonist AMD3100 Mobilizes a More Primitive Subset of CD34+ Cells Than G-CSF.

AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma.

A Pilot Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients with Advanced Hematological Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only